<DOC>
	<DOC>NCT02658890</DOC>
	<brief_summary>The purpose of the study is to determine the safety and effectiveness of experimental medication BMS-986205, when combined with Nivolumab in patients with cancers that are advanced or have spread.</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab in Cancers That Are Advanced or Have Spread.</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb(BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Patients must have been diagnosed with cancer and had at least 1 prior standard treatment Must be able to swallow pills or capsules Eastern Cooperative Oncology Group(ECOG) Performance Status 01 Any prior ongoing clinical study with Nivolumab with overall survival as an endpoint Requirement for daily supplemental oxygen Myocardial infarction or stroke/transient ischemic attack within the past 6 months Uncontrolled angina within the past 3 months History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency virus(HIV), or acquired immune deficiency syndrome(AIDS) Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>